Drug intelligence / Profile preview

PliaFX

Development stage: Unknown
Lead developer: LifeNet Health
Administration: Topical

Overview

PliaFX is a family of demineralized bone matrix (DBM) products developed by LifeNet Health and distributed through Johnson & Johnson MedTech. It is a bone graft material used as a bone void filler in orthopedic and spine procedures. The product consists of demineralized bone fibers with a proprietary microhook structure designed to promote osseointegration and bone formation. The portfolio includes various formulations such as PliaFX Prime (100% bone fiber), PliaFX Flo (with a glycerol carrier), and PliaFX Pak (a blend with bone chips). These products are indicated for treating bony voids or gaps in the skeletal system, including the extremities, spine, and pelvis, as well as surgically created or traumatic osseous defects.

Brand names: PliaFXPliaFX PrimePliaFX FloPliaFX Pak
Other names: PliaFX Advanced Fiber technology

Beyond the preview

Go deeper on PliaFX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PliaFX.

Explore the full profile